SR 29001

Drug Profile

SR 29001

Latest Information Update: 15 Sep 1998

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi-Synthelabo
  • Class Hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Growth disorders

Most Recent Events

  • 15 Sep 1998 Discontinued-preregistration for Growth disorders in European Union (Unknown route)
  • 23 Dec 1996 Preregistration for Growth disorders in European Union (Unknown route)
  • 04 Sep 1996 Investigation in Growth disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top